ストックスクリーナーアプリを入手
2.53
2.32%
-0.06
Sab Biotherapeutics Inc (SABS) 最新ニュース
SAB Biotherapeutics Warrant (SABSW) Trades Flat at $0.01 as Directional Signals Remain ElusiveProtective Put - siam.in
SAB Biotherapeutics Warrant (SABSW) Trades Flat at $0.01 as Directional Signals Remain ElusiveSupply Zone - https://www.dars.gov.et/
SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes - Yahoo Finance
Tax withholding trims SAB Biotherapeutics (SABS) CMO stake - Stock Titan
SAB BIO at Citi summit: trial progress and a bigger t1d bet By Investing.com - Investing.com South Africa
SAB BIO at Citi summit: trial progress and a bigger t1d bet - Investing.com India
SAB BIO at Citi summit: trial progress and a bigger t1d bet - Investing.com UK
SAB BIO to Participate in Upcoming Investor Conferences - GlobeNewswire
SAB BIO to Participate in Upcoming Investor Conferences - Yahoo Finance
SAB Biotherapeutics Inc. (SABS) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
SAB Biotherapeutics Inc. Warrant (SABSW) Key Financial Ratios – Valuation, Profitability & More - Value Research
SAB (SABSW) Market: Ends Higher by 13.58% at $0.03 in the Current Update; Range Check - vinanet.vn
SAB (SABSW) Session: Moves 7.02% Down to $0.03 at the Close; Boundary Watch - vinanet.vn
SAB (SABS) Today: Posts a 2.16% Gain to $3.78 in the Current Update; Price Setup: the Current Price Sits Inside the Supplied Technical Range in the Latest SessionLiquidity Sweep - vinanet.vn
SAB (SABS) Today: Posts a 2.16% Gain to $3.78 in the Current Update; Price Setup: the Current Price Sits Inside the Supplied Technical Range in the Latest SessionCash Secured Put - vinanet.vn
SAB (SABSW) Latest: Falls 14.29% to $0.02 in the Current Update; Level Watch - vinanet.vn
There are notable gap-ups and gap-downs in today's session. - ChartMill
Price to earnings forward of SAB Biotherapeutics, Inc. – BOATS:SABSW - TradingView
Balyasny Asset Management L.P. Expands Stake in SAB Biotherapeutics Inc (SABS) - GuruFocus
SAB (SABS) Earnings Update: EPS Prints Above Forecast in the Current Update; Market Move: Shares Move Lower 0.26% in the Latest SessionEPS Miss Report - dars.gov.et
SAB (SABS) Earnings Update: EPS Prints Above Forecast in the Current Update; Market Move: Shares Move Lower 0.26% in the Latest SessionROE Trend Analysis - vinanet.vn
SAB Biotherapeutics (SABS) Slips 1.33% to $3.70 as Support Level Comes into FocusCash Flow Strong Stocks - vinanet.vn
SAB Biotherapeutics (SABS) Slips 1.33% to $3.70 as Support Level Comes into FocusRevenue Growth Stocks - dars.gov.et
Perceptive Advisors discloses 7.3% SAB Biotherapeutics (SABS) stake via Master Fund - Stock Titan
Caligan Partners (SABS) discloses 7.97M SAB Biotherapeutics shares in amended 13G - Stock Titan
Commodore Capital discloses 8.95M-share position in SAB Biotherapeutics (SABS) - Stock Titan
Vivo funds (SABS) report capped 9.99% stakes via preferred stock and warrants - Stock Titan
Woodline Partners (SABS) discloses 5.46M-share beneficial stake in SAB Biotherapeutics - Stock Titan
Balyasny Asset Management (SABS) discloses 7.2M-share SAB Biotherapeutics position capped at 9.99% - Stock Titan
Adage discloses 8.38% SAB Biotherapeutics (SABS) ownership in Schedule 13G - Stock Titan
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
SABS Q2 2026 Earnings: Narrower-than-Expected Loss, Yet Stock SlipsROIC Trend Report - dars.gov.et
RA Capital group discloses 9.9% SAB Biotherapeutics (SABS) stake capped by ownership blockers - Stock Titan
What is HC Wainwright's Estimate for SABS Q3 Earnings? - MarketBeat
Q3 EPS Estimate for SAB Biotherapeutics Boosted by Analyst - MarketBeat
SAB Biotherapeutics (NASDAQ:SABS) Upgraded by Wall Street Zen to "Sell" Rating - MarketBeat
H.C. Wainwright Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $10 - Moomoo
SAB Biotherapeutics Q2 Earnings Call Highlights - MarketBeat
SAB Biotherapeutics Q2 Earnings Call Highlights - Yahoo Finance
SABS FY2030 EPS Boosted by Brookline Capital Markets - marketbeat.com
SAB Biotherapeutics (SABS) Rises 1.43% to $3.9 — Key Resistance at $4.09 in FocusTriple Bottom - vinanet.vn
SAB Biotherapeutics (NASDAQ:SABS) Posts Earnings Results, Hits Estimates - MarketBeat
SAB Biotherapeutics Inc (SABS) (Q2 2026) Earnings Call Highlights: Advancing SAB142 with Strong ... - Yahoo Finance
Earnings call transcript: SAB Bio posts wider Q2 2026 loss as trial momentum builds - Investing.com Nigeria
SAB Biotherapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
SAB Biotherapeutics, Inc. Q2 2026: Net loss $(22.5M), EPS $(0.28) — 10-Q Summary - TradingView
SAB Biotherapeutics (NASDAQ: SABS) posts Q2 loss after March 2026 stock offering - Stock Titan
SAB BIO Reports Q2 2026 Results, Expands SAB-142 Type 1 Diabetes Trials and Secures Breakthrough T1D Grant for PRISE-hATG Study - Quiver Quantitative
SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights - The Manila Times
Press Release: SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights - Moomoo
4.22%
大文字化:
|
ボリューム (24 時間):